Trial Profile

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 06 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Cyclophosphamide; Doxorubicin; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Adverse reactions
Acronyms AvR-CHOP

Most Recent Events

18 Jul 2022 Planned primary completion date changed from 1 Feb 2021 to 1 Sep 2022.
18 Jul 2022 Status changed from recruiting to active, no longer recruiting.
08 Dec 2020 Results (n=28) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com